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Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset syndrome
characterized by progressive degeneration of speciﬁc muscles. OPMD is caused
by extension of a polyalanine tract in poly(A) binding protein nuclear 1 (PABPN1).
Insoluble nuclear inclusions form in diseased muscles. We have generated a
Drosophila model of OPMD that recapitulates the features of the disorder. Here,
we show that the antiprion drugs 6-aminophenanthridine (6AP) and guanabenz
acetate (GA), which prevent formation of amyloid ﬁbers by prion proteins in cell
models,alleviate OPMD phenotypesinDrosophila,including muscle degeneration
and nuclear inclusion formation. The large ribosomal RNA and its activity in
protein folding were recently identiﬁed as a speciﬁc cellular target of 6AP and GA.
We show that deletions of the ribosomal DNA locus reduce OPMD phenotypes
and act synergistically with sub-effective doses of 6AP. In a complementary
approach, we demonstrate that ribosomal RNA accelerates in vitro ﬁbril for-
mation of PABPN1 N-terminal domain. These results reveal the conserved role of
ribosomal RNA in different protein aggregation disorders andidentify 6AP and GA
as general anti-aggregation molecules.
INTRODUCTION
Protein aggregation diseases form a set of disorders that are
characterized by intracellular aggregation and deposition of
pathogenic proteins in the form of insoluble inclusions or
plaques (Taylor et al, 2002). Most of these diseases are
neurodegenerative, including prion-based diseases, Alzheimer’s,
Parkinson’s, as well as Huntington’s and other polyglutamine
expansion-based diseases. Polyglutamine diseases result from
triplet expansion leading to an increased length of a poly-
glutamine tract. The protein with an expanded polyglutamine
tract aggregates as inclusions in affected cells (Cooper et al,
1998; Davies et al, 1997; DiFiglia et al, 1997). However, whether
the mature insoluble ﬁbril or an oligomeric intermediate play
a role in the pathology remains unknown. A protective role
of inclusions has even been described (Arrasate et al, 2004).
Anti-aggregation drugs, such as trehalose, that can reduce
the number of inclusions in a cell model of Huntington’s
disease, have also a beneﬁcial effect in a mouse model (Tanaka
et al, 2004), indicating that either inclusions per se or the
process of inclusion formation is an important aspect in
pathogenesis.
Oculopharyngeal muscular dystrophy (OPMD) is another
triplet expansion disease in which the mutation expands a
polyalanine tract. The affected protein, poly(A) binding protein
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initiation codon in its normal form, and this tract is expanded to
12–17 in the mutant forms found in OPMD patients (Brais et al,
1998). PABPN1 is an ubiquitous protein with general and
essential functions in messenger RNA (mRNA) polyadenylation
(Benoit et al, 2005; Wahle, 1991, 1995). During the process of
nuclear polyadenylation, PABPN1 binds to nascent poly(A) tails
and has two roles: stimulation of poly(A) polymerase, and
control of poly(A) tail length (Ku ¨hn & Wahle, 2004; Wahle,
1991). Despite the general and ubiquitous function of PABPN1,
OPMD affects particular muscles and the disease is character-
ized by eyelid drooping, swallowing difﬁculties and proximal
limb weakness (Brais, 2003). OPMD is a dominant and
progressive genetic disorder that has a late onset. As in
polyglutamine expansion diseases, the mutant protein aggre-
gates and forms insoluble nuclear inclusions, in that case in
affected muscles. Because nuclear inclusions are characteristic
of the disease, alanine expansion contributes in some way to the
formation of the inclusions. However, normal PABPN1
oligomerizes during its function in polyadenylation. Moreover,
aggregation of the normal protein has been observed in rat
hypothalamus neurons (Berciano et al, 2004). In animal and cell
models of OPMD, overexpression of normal PABPN1 or
PABPN1 deleted for the polyalanine tract also leads to the
formation of nuclear inclusions (Chartier et al, 2006; Fan et al,
2001; Tavanez et al, 2005). Therefore, a possibility could be that
the polyalanine tract extension modiﬁes the turnover or
properties of the protein, leading to increased accumulation
and/or accelerated inclusion formation. OPMD nuclear inclu-
sions contain poly(A) ribonucleic acid (RNA), ubiquitin,
proteasome subunits and chaperone proteins such as heat-
shockprotein70(HSP70)andhumanDNAJhomologue-1(HDJ-1)
(Abu-Baker et al, 2003; Calado et al, 2000). In cell models of
OPMD, reducing aggregation with drugs or by overexpressing
HSP70 decreases cell death (Bao et al, 2004). This suggests that
either the presence of PABPN1 inclusions and/or the process of
aggregation itself contribute to the pathology. Consistent with
this, we found that overexpression of HSP70 is a suppressor of
muscular defects in the Drosophila model of OPMD (Chartier
et al, 2006). Moreover, anti-aggregation drugs doxycycline and
trehalose reduce the number of nuclear inclusions and muscle
weakness in a mouse model of OPMD (Davies et al, 2005, 2006).
6-Aminophenanthridine (6AP) and guanabenz acetate (GA)
were isolated as active against yeast prions using a yeast-based
assay and appeared to be also active against mammalian prion
(Bach et al, 2003; Tribouillard et al, 2006; Tribouillard-Tanvier
et al, 2008a). The fact that 6AP and GA (as well as other
antiprion drugs) are active against different prion proteins, in
bothyeastandmammaliansystems,stronglysuggeststhatthese
compounds interfere with evolutionary conserved prion-con-
trollingmechanismsthatmaybeinvolvedinproteinfolding.We
therefore hypothesized that these compounds could be
beneﬁcial for other protein folding associated diseases, includ-
ing Huntington’s disease. Consistent with this, we recently
found that 6AP and GA, as well as several other antiprion drugs
isolated using the yeast-based assay, were able to reduce
aggregates formed by mutated huntingtin in cell-based assays
(European patent: ‘Use of chlorine guanabenz derivatives for
treating polyglutamine expansion associated diseases’ A.
Bertolotti and M. Blondel, CNRS, no. 06291547.6).
Interestingly, a speciﬁc cellular target of both 6AP and GA
was recently identiﬁed to be the ribosome-borne protein folding
activity of the large ribosomal RNA (Tribouillard-Tanvier et al,
2008b). Although they are structurally unrelated (Fig 1A), both
drugs interact with the ribosome in an RNA-dependent manner
and bind to common speciﬁc positions in domain V of the large
ribosomal RNA. Strikingly, these interactions have no effect on
the peptidyl transferase activity of the ribosome or on global
translation, however, they speciﬁcally inhibit the ability of the
ribosome to assist protein folding in vitro, another largely
unexplored activity of the ribosome (Tribouillard-Tanvier et al,
2008b). Importantly, inactive 6-aminophenanthridine (6APi), a
close chemical derivative of 6AP, that is inactive against both
yeast and mammalian prions, is also unable to interact with
domain V of the large ribosomal RNA and to inhibit its protein
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Figure 1. 6AP, 6APi and GA structures, and toxicity of drugs fed to larvae.
A. The molecular structures of 6AP, of its less active chemical derivative 6APi
and of GA are shown.
B. Toxicity of the drugs fed to larvae was determined by transferring 80 wild-
type first instar larvae into vials containing 5ml of instant Drosophila
medium reconstituted either with increasing concentrations of drug in
DMSO or with DMSO alone. Puromycin was diluted in water. The graph
shows the percentage of flies reaching adulthood at 258C( n¼120–360).
Drugs provided to adults were found to be non-toxic, as determined by the
lack ofmortality ofadults fedwith drug-supplementedmediumduring the
course of the experiment.
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the ribosome in protein folding may play a role in prion
propagation and aggregate formation.
We previously developed a Drosophila model of OPMD that
recapitulates the characteristics of the disease including
progressive muscle degeneration with muscle defects propor-
tional to the number of alanines in the tract and formation of
PABPN1 nuclear inclusions (Chartier et al, 2006). Here, we
showthat6APandGAarebeneﬁcialforOPMDintheDrosophila
model. Feeding animals with both drugs decreases muscle
degeneration and reduces the size of nuclear inclusions. We
observe a synergistic effect of 6AP with deletions of the
ribosomal DNA locus, suggesting that the ribosomal RNA is a
conserved cellular target of 6AP in Drosophila. Moreover,
domain V of the large ribosomal RNA, that bears the protein
folding activity and is targeted by 6AP and GA, accelerates ﬁbril
formation of the alanine expanded N-terminal domain of
PABPN1 in vitro. Together, these data strongly suggest that
the protein folding activity of the large ribosomal RNA plays a
role in PABPN1 aggregation in OPMD, and strengthen the
hypothesis that ribosomal RNA has a general function in the
formation of disease-related amyloid ﬁbers. These data also
highlight 6AP and GA as general anti-aggregation drugs that
might be beneﬁcial for major protein folding diseases. Because
GA is routinely used as a treatment against hypertension
without major side-effects, our results reveal GA as a strong
candidate in potential treatments for OPMD and other protein
aggregation disorders.
RESULTS
The Drosophila model of OPMD was generated by expressing
mammalian alanine expanded PABPN1, PABPN1-17ala, with the
upstream activation sequence (UAS)/GAL4 transcription factor
(Gal4) system (Brand & Perrimon, 1993; Chartier et al, 2006).
Expression was driven in muscles using the myosin heavy chain
(Mhc)-Gal4 driver (Schuster et al, 1996). PABPN1-17ala expres-
sion with Mhc-Gal4 leads to progressive wing position defects,
progressive muscle degeneration visualized in thoracic indirect
ﬂight muscles (IFMs), and formation of PABPN1 nuclear inc-
lusions that were analyzed in larval and adult thoracic muscles.
6AP decreases the wing position phenotypes induced by
expression of PABPN1-17ala in muscles
Because OPMD pathology involves protein aggregation, we
tested whether drugs known to have anti-aggregation properties
could be effective for OPMD using the Drosophila model. Drugs
were provided in the food from larval stages to adulthood. The
toxicity of the drugs was assessed by measuring the viability of
individuals raised on drug-supplemented medium from larval
stages (Fig 1B, Supplementary Figs 1 and 2). Both doxycycline
andtrehalosehaveabeneﬁcialeffectinamousemodelofOPMD
(Davies et al, 2005, 2006), and ibuprofen reduces PABPN1
aggregation in a cell model of OPMD (Wang et al, 2005). We
found that none of these drugs were effective in the Drosophila
model (Supplementary Fig 1). We next tested the effect of 6AP,
another anti-aggregation drug with antiprion activity. 6APi, a
close chemical derivative of 6AP that was described as inactive
or less effective in antiprion assays both in yeast and mammals,
was used as a negative control (Fig 1A). Toxicity tests showed
substantial survival of individuals fed with up to 400mMo f
drugs. In the presence of 600mM of 6AP, development was
delayed and viability was dramatically decreased (Fig 1B,
Supplementary Fig 2). We therefore used 400mM as the highest
concentration to feed larvae in further studies.
Expression of PABPN1-17ala with Mhc-Gal4 leads to
progressive defects in wing position (wings up or down). At
188C, abnormal wing position appears at day 3 of adulthood
with less than 20% of individuals showing defects, and this
percentage reaches 90% at day 6 (Chartier et al, 2006). We
analyzed the effect of feeding OPMD larvae and adults with
increasing concentrations of 6AP, ranging from 250 to 400mM.
Wing position defects were scored at day 6 of adulthood, when
90% of individuals show defects in the absence of the drug
(Fig 2A). A dose-dependent beneﬁcial effect of 6AP was visible.
The strongest effect was obtained in the presence of 400mM
6AP, the percentage of individuals with wing position defects
decreased to 50%. An identical experiment performed in the
presenceofthecontrolmolecule6APishowedthatthismolecule
had no effect (Fig 2A). We found that 400mM of 6AP was still
beneﬁcial, although to a lesser extent, when provided during
larval stages only, or from third instar larval to adult stages
(Supplementary Fig 3). We veriﬁed that the positive effect of
6AP did not result from reduced levels of PABPN1-17ala in
thoracic muscles of individuals fed with 6AP (Fig 2B).
We next determined whether 6AP could also have a
protective effect when provided at later stages. Expression of
PABPN1-17ala with Mhc-Gal4 does not affect IFM development
as these muscles do not appear altered in early adulthood
(Chartier et al, 2006). We therefore provided the drug to OPMD
adults at 188C starting the day of birth (day 1) and scored wing
position defects at day 6. Feeding adults with 400mM of 6AP led
to a weak decrease in the percentage of ﬂies showing wing
position defects (Fig 2C). We used higher concentrations of
6AP, from 1 to 3mM, which were found to be non-toxic when
providedtoadultsonly.Withtheseconcentrations,thepercentage
of affected ﬂies decreased signiﬁcantly to 70%. A plateau was
reached from 1mM of 6AP, as the beneﬁcial effect of the drug did
not improve with higher concentrations. Therefore, 6AP provided
to adults was also beneﬁcial and its protective effect was dose-
dependent. We found that 6AP at 1mM remained beneﬁcial
when provided to adults at day 2 (Fig 2D).
To address whether 6AP could have a curative effect on
individuals already showing wing position defects, we selected
adults with affected wing position at day 3, fed them with 1mM
of 6AP and analyzed their wing position at day 4 (after 24h).
Because wingposition defects are not stabilizedat day 3,15% of
individualsshowednormalwingpositionatday4whenfedwith
dimethyl sulphoxide (DMSO) alone. However, the percentage of
ﬂies with normal wing position at day 4 signiﬁcantly increased
to 33% in individuals fed with 6AP (Fig 2E).
Together, these results show that the antiprion compound
6AP is effective to reduce the phenotype of OPMD, a protein
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The protective role of 6AP is dose-dependent and the drug also
shows some extent of curative effect.
GA decreases OPMD wing posture phenotypes when fed to
adults
Guanabenz acetate is another antiprion drug which appears to
have the same mode of action as 6AP (i.e. binding to ribosomal
RNA and speciﬁc inhibition of its protein folding activity), we
thus tested its potential efﬁciency in OPMD. GA is known to be
an unstable molecule. It was reported to have a half-live of a few
hours in the human body (Holmes et al, 1983). We therefore
provided GA to OPMD adults only and supplied fresh GA-
supplemented medium at several time points during the
experiment. No toxicity of GA was observed when provided
to adults (94% of survival at day 6 (n¼87), when 3mM GA was
provided fresh every day). In a ﬁrst experiment, adults were fed
with GA at day 1 and fresh GA-supplemented medium at the
same concentration wasprovided atdays 3and 5.Wing position
defects were recorded at day 6. A dose-dependent beneﬁcial
effectofGAwasobserved,withadecreaseto50%ofindividuals
showing wing position defects when fed with 3mM of GA
(Fig3A).Wethen analyzedtheeffectofthedrugwhenfreshGA-
supplemented medium was supplied every day and the
treatment started at later stages. Consistent with the short
half-life of the drug, the positive effect of GA was increased in
these conditionswithareduction to49%ofindividuals showing
wing position defects at day 6 in the presence of 2mM of GA
(Fig 3B). This effect occurred when GA was provided from
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Figure 2. 6AP reduces the wing position defects resulting from expression
of alanine-expanded PABPN1 in muscles.
A. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ first instar larvae were raised at 188C
on instant Drosophila medium supplemented with increasing concen-
trations of 6AP, 6APi or DMSO alone. The day of birth (day 1), adult males
were transferred onto fresh medium with the same concentration of
drug and scored for wing position at day 6 (n¼120–320). Oral admin-
istration of 6AP reduces the percentage of wing position defects in a dose-
dependent manner (left panel),whereas6APi shows noeffect(rightpanel).
B. Western blot of thorax protein extracts from UAS-PABPN1-17ala/þ;
Mhc-Gal4/þ individuals at day 6, fed from larval stages with 400mMo f
6AP or DMSO alone. The blot was probed with anti-PABPN1, a-tubulin
was used as a loading control.
C. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ embryos were raised on regular
Drosophila medium at 188C. The day of birth (day 1), adult males were
transferred onto fresh instant Drosophila medium supplemented with
6AP, 6APi or DMSO alone. Wing position defects were scored at day 6
(n¼40–120). Because of the shorter period of exposure to the drug and
the reduced taking of food by adults compared to larvae, concentrations
of 6AP higher than 400mM were found to be non-toxic.
D. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ adults were transferred to 6AP or
DMSO alone-supplemented medium at day 2. Wing position defects were
scored at days 4, 5 and 6 (n¼112–119).
E. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ adults with wing position defects
were selected at day 3 and transferred immediately to 6AP or DMSO
alone-supplemented medium, wing position defects were scored at day
4( n¼100).
   p-value <10
 4,
  p-value<0.01 and
 p-value<0.05 using
the x
2 test.
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stage, from day 3 of adulthood, the 2mM dose was not
signiﬁcantly effective, however, a signiﬁcant decrease to 48% of
individuals having wing position defects at day 6 was observed
with 3mM GA (Fig 3C).
We used GA at the concentration of 3mM, supplied fresh
every day, to analyze a potential curative effect on individuals
showing wing position defects at day 3. A signiﬁcant reduction
in the percentage of ﬂies with wing position defects at day 4 was
observed in the presence of 3mM of GA compared to DMSO
alone, indicating a curative effect of GA (Fig 3D).
We veriﬁed that the beneﬁcial effect of GA was not due to a
reduction of PABPN1-17ala protein levels in thoracic muscles
(Fig 3E).
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Figure 3. GA reduces the wing position defects of
OPMD individuals when provided to adults.
A. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ embryos were
raised on regular medium at 188C, adult males
were transferred to GA or DMSO supplemented
medium at day 1 and transferred to fresh
supplemented medium at days 3 and 5. Wing
position defects were scored at day 6 (n¼49).
B. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ adult males
were transferred to GA or DMSO supplemented
medium at day 2 and transferred to fresh
supplemented medium every day. Wing position
defects were scored at days 4, 5 and 6 (n¼49).
C. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ adult males
without wing position defects were selected at
day 3 and transferred to GA or DMSO supple-
mented medium. They were transferred to
fresh supplemented medium every day. Wing
position defects were scored at days 4, 5 and
6( n¼50–80).
D. UAS-PABPN1-17ala/þ; Mhc-Gal4/þ adult males
showing wing position defects were selected at
day3 and immediatelytransferred to GA or DMSO
supplemented medium. Wing position defects
were scored at day 4 (n¼65–84).
   p-value
<10
 3,
  p-value<0.01 and
 p-value <0.05
using the x
2 test.
E. Western blot of thorax protein extracts from
UAS-PABPN1-17ala/þ; Mhc-Gal4/þ individuals at
day 6, fed with 3mM GA or DMSO alone from day
2 of adulthood, transferred to fresh medium
everyday.The blotwas probedwithanti-PABPN1,
a-tubulin was used as a loading control.
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of GA in reducing the appearance of OPMD phenotypes when
providedtoadults, evenatlate stages.In addition, GAalsohada
curative effect on individuals already showing defects.
6AP and GA decrease muscle degeneration induced by
expression of PABPN1-17ala
Expression ofPABPN1-17ala with Mhc-Gal4 leadstoprogressive
muscle degeneration as visualized by polarized light on thoracic
IFMs, which are involved in ﬂight and wing posture (dorso-
longitudinal muscles: DLMs or dorso-ventral muscles: DVMs)
(Chartier et al, 2006, 2009). We analyzed muscle degeneration
withpolarized light afterexpression of PABPN1-17ala with Mhc-
Gal4 at day 11, by scoring the number of affected muscles (six
DLMs and seven DVMs per thorax). In the absence of drug,
defects were visible in most IFMs which appeared thin or were
lacking (Fig 4A–E). In the presence of either 400mM of 6AP
provided from larval stages or 3mM of GA provided to adults
and supplied fresh every day, muscle degeneration was strongly
reduced (Fig 4A–E). Because in the presence of the drugs, not all
ﬂies had normal wing position, we scored muscle defects
separately in ﬂies with normal (rescue) and affected (no rescue)
wing posture. Indeed, normal wing posture requires both
normal muscle structure and function. Therefore, we reasoned
thatthelevelofrescueinthepresenceofdrugsmightbehigherif
we analyzed muscle morphology rather than muscle function
(i.e. wing position). Strikingly, muscle degeneration was largely
prevented in ﬂies with normal wing posture and this beneﬁcial
effect was also visible in ﬂies with affected wing posture,
although it was less pronounced in these ﬂies (Fig 4D and E).
This indicates that after drug treatment, ﬂies that still have an
abnormal wing posture can show some rescue of muscle
morphology.
These data conﬁrm that both 6AP and GA are beneﬁcial for
OPMD. Both drugs reduce the main defect in the pathology
which corresponds to muscle weakness and degeneration.
6AP and GA reduce the size of PABPN1 nuclear aggregates
An important aspect of OPMD pathology is the formation of salt
extraction-resistant nuclear aggregates containing PABPN1 in
muscle ﬁbers from OPMD patients. We have shown that the
Drosophila model of OPMD reproduces the presence of these
aggregates which are very similar to aggregates observed in
patients, both in composition and in structure. In Drosophila,
PABPN1-17ala-containing nuclear inclusions are resistant to
1M KCl extraction and recruit HSP70 and ubiquitin. When
visualized by electron microscopy (EM), these inclusions are
composed of unbranched tubular ﬁlaments closely resembling
the ﬁlaments observed in nuclear inclusions in OPMD patients
(Chartier et al, 2006). The 6AP and GA molecules were reported
to have anti-aggregation properties. We tested whether the
protective effect of these drugs for OPMD correlates with an
ability to reduce aggregation of PABPN1-17ala. 6AP and 6APi
were provided from larval stages at 400mM and nuclei
containing an inclusion were quantiﬁed in thoracic muscles
expressingPABPN1-17alaatday11.Thesenucleirepresent18%
of nuclei when larvae were fed with DMSO alone (Fig 5A). The
percentage of nuclei with a nuclear inclusion was not reduced
when larvae were fed with 6APi or 6AP (Fig 5A). However, 6AP
treatment had a signiﬁcant and speciﬁc effect in reducing the
size of nuclear inclusions (Fig 5B and E). No signiﬁcant
difference in the size of the nuclear inclusions was observed
between individuals fed with 6AP that had either a rescued or a
non-rescued wing posture. However, it is important to note that
ﬂies with affected wing position showed some rescue of muscle
morphology (Fig. 4). Therefore, there was a correlation between
the reduced size of nuclear inclusions and the rescue of muscle
morphology.
ToanalyzetheeffectofGA,thedrugwasprovidedtoadultsat
3mM, supplied fresh every day, and PABPN1-17ala nuclear
inclusions in thoracic muscles were scored at day 6. Thirteen
percentofnucleicontainaninclusionwhenadultswerefedwith
DMSOalone(Fig5C).Thelowernumberofnuclearinclusionsat
day 6 compared to day 11 is consistent with our previous data
showing that the number of inclusions increases with the age of
the ﬂies (Chartier et al, 2006). As it was the case for 6AP, the
percentage of nuclei with an inclusion was similar in the
presence of GA or DMSO alone (Fig 5C). However, nuclear
inclusions were signiﬁcantly smaller after treatment with GA
than in the control (Fig 5D and E).
We conclude that both 6AP and GA interfere with the
aggregation process of alanine-expanded PABPN1, eventually
leading to the formation of smaller aggregates.
6AP acts synergistically with deletions of the ribosomal DNA
locus to reduce OPMD phenotypes
The ribosomal RNA has been identiﬁed as a speciﬁc cellular
target of both 6AP and GA. Both drugs bind speciﬁcally to
several common positions in domain V of the large ribosomal
RNA and these interactions prevent the ribosomal RNA-
mediated activity in protein folding, as assessed in vitro and
in an in vivo test in bacteria (Tribouillard-Tanvier et al, 2008b).
If the beneﬁcial effect of 6AP and GA on OPMD in Drosophila
also results from a reduced activity of the large ribosomal RNA,
a similar beneﬁcial effect might be observed with mutants
affecting ribosomal RNA activity. The ribosomal DNA locus,
called bobbed (bb)i nDrosophila, is composed of 120–240
tandem repeats on each of chromosomes X and Y. These repeats
encodethe18S,5.8S,2Sand28SribosomalRNA(Long&Dawid,
1980). We used bb
N, a weak allele of bb, in which a small
number of repeats is deleted, and Df(1)17-87, a complete
deletionof theregionincluding the wholebb locus, todetermine
whether genetically decreasing the copy number of ribosomal
DNA repeats would affect OPMD phenotypes. We veriﬁed that
none of the bb mutant combinations showed abnormal wing
posture independently of OPMD. Each of the bb deletions alone
had no signiﬁcant effect on the percentage of OPMD ﬂies with
wing posture defects. However, when both deletions (bb
N/
Df(1)17-87) were combined in OPMD ﬂies, we observed a
signiﬁcant decrease in the number of these ﬂies showing wing
position defects (Fig 6B). To determine whether the beneﬁcial
effect of 6AP on OPMD could occur through the modulation
of ribosomal RNA activity, we analyzed if 6AP could act
synergisticallywithareductionofthecopynumberofribosomal
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N/þ and Df(1)17-87/þ
mutations, nor 6AP at 250mM had an effect on OPMD wing
position defects (Fig 2A, 6B). However, the combination of
both bb
N/þ or Df(1)17-87/þ and 250mM of 6AP strongly
decreased the percentage of OPMD ﬂies with wing posture
defects (Fig 6C). This shows that 6AP and deletions of the
ribosomal DNA locus act synergistically and strongly suggests
that the ribosomal RNA is also a cellular target of 6AP in
Drosophila. It should be noted that, because the survival of bb
N/
Df(1)17-87 ﬂies raised on DMSO alone or 400mM of 6AP was
very low (<10%), wing position was not scored in these
conditions.
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Figure 4. 6AP and GA reduce muscle degeneration induced by expression of PABPN1-17ala.
A. Dorso-longitudinal(DLM)anddorso-ventral(DVM)adultthoracicmusclesvisualizedwithpolarizedlight.Examplesofmusclesatday11,fromwildtype(wt)
raised on DMSO. Six DLMs (1–6) and six DVMs (I1, I2, II1, II2, III1, III2) are visible; DVM I3 is out of focus (
 ). Anterior is to the left, dorsal is up.
B. DLMs and DVMs at day 11, of OPMD (UAS-PABPN1-17ala/þ; Mhc-Gal4/þ) flies fed with DMSO alone or 400mM 6AP from larval stages. Arrows indicate very
thin or missing muscles. Muscles with a normal appearance from flies fed with 6AP are shown (OPMD (6AP)).
C. DLM and DVM at day 11, of OPMD flies fed with DMSO alone or 3mM GA from day 2 of adulthood and transferred to fresh supplemented medium every day.
Arrows indicate very thin or missing muscles. Muscles with a normal appearance from flies fed with GA are shown (OPMD (GA)).
D, E. Percentages of affected muscles either in the absence (DMSO), or in the presence of drugs (6AP or GA). Six DLMs and seven DVMs were scored per thorax
(n¼48–169 DLM and 70–322 DVM). Muscles were also scored separately, in subgroups showing or not wing position defects after drug treatment. ‘6AP or
GArescue’indicates OPMDfliesraisedondrug-supplementedmedium,whichhavenormalwing posture,‘6APorGAnorescue’indicates fliesraisedondrug-
supplemented medium, which still have an affected wing posture.
   p-value <10
 3 using the x
2 test.
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ribosomal RNA does not affect protein synthesis, both in vivo in
yeast and in in vitro translation system based on rabbit
reticulocyte lysate (Tribouillard-Tanvier et al, 2008b). We
veriﬁed that the decrease of OPMD phenotypes in bb
N/Df(1)17-
87 mutant ﬂies did not result from a lower production of
PABPN1-17ala in this context (Fig 6D). To conﬁrm that the
beneﬁcial effect of 6AP on the Drosophila model of OPMD did
not depend on a global decrease in protein synthesis, we studied
the effect on OPMD phenotypes of puromycin, a general protein
synthesis inhibitor. The toxicity of this drug allowed its
utilization up to 600mM (Fig 1B). Wild-type ﬂies fed from
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Figure 5. 6AP and GA reduce the size of
PABPN1-17ala nuclear inclusions in Drosophila
muscles.
A. Percentages of nuclear inclusions in OPMD
(UAS-PABPN1-17ala/þ; Mhc-Gal4/þ)
thoracic muscles. Larvae were raised in the
presence or absence of drug, and adult
thoracic muscles were dissected at day 11
and stained with anti-PABPN1 and DAPI.
Nuclear inclusions were visualized and
scored using both staining.
B. Quantification of nuclear inclusion areas.
Each nuclear inclusion was delimited in a
focal plan and the surface area was
calculated using Image J. Mean values of
the surface areas are shown in arbitrary
units (top). Distribution of nuclear
inclusion surface areas are shown as box
plots (bottom). The boxes represent 50% of
the values, horizontal lines correspond to
the medians (50% of the values on each
side of the line), vertical bars correspond to
the range. Extreme values are in open
circles.
    Distributions are different using
the Student’s t-test, p-value <10
 4,n s :
non-significant. After drug treatment,
quantifications are indicated both
regardlessofthewingposture(6AP),andin
subgroups showing or not wing position
defects (6AP no rescue and 6AP rescue). ‘no
rescue’ indicates flies which still have an
affected wing posture, ‘rescue’ indicates
flies with normal wing posture.
C, D. Percentages of nuclear inclusions (C) and
quantification of nuclear inclusion areas
(D) in OPMD thoracic muscles either in the
presence or absence of 3mM of GA
provided fresh every day, from day 2 of
adulthood. Nuclear inclusions were scored
at day 6. Legend is as in (A, B).
E. Confocal images of nuclear inclusions
visualized with anti-PABPN1 staining. DNA
was revealed with DAPI. In OPMD indi-
viduals fed with DMSO alone, nuclear
inclusions are large and can occupy most
of the nucleus (inclusion). An example of
nucleus without inclusion is shown for
comparison (no inclusion). Nuclear
inclusions were smaller when flies were
raised on drug-supplemented medium.
Examples of small inclusions at day 11 in
the presence of 400mM of 6AP from larval
stages (OPMD (6AP)), and at day 6 in the
presence of 3mM of GA from day 2 of
adulthood, provided fresh every day
(OPMD (GA)).
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had a delayed development, starting from 300mM, consistent
with reduced protein synthesis. However, up to 600mM of this
drug had no effect on the number of OPMD ﬂies showing
abnormal wing posture (Fig 6E). Together, these results suggest
that the beneﬁcial effect of 6AP in OPMD does not result from
reduced protein synthesis, either global or speciﬁcally for
PABPN1-17ala.
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Figure 6. The ribosomal RNA is a cellular target of 6AP.
A. Abbreviations and genotypes used in Figs 6 and 7.
B. Percentages of wing position defects in OPMD flies at 188C, in the presence or absence of bb mutations. Note that because the bb locus is on chromosome X,
females were scored in these experiments (n¼140–220). The percentage of abnormal wing position in OPMD females (73–77%) is lower than in males (90%,
Fig 2).
C. Synergy between bb mutants and 6AP. Percentages of wing position defects in OPMD flies at 188C at day 6, either in the presence or absence of bb mutations
and 250mM of 6AP. OPMD females were scored (n¼70–110).
   p-value <10
 4 using the x
2 test.
D. Western blot of protein extracts from adult female thoraxes at day 6, showing that the expression of PABPN1-17ala is not affected in bb mutants. Theblot was
probed with anti-PABPN1, a-tubulin was used as a loading control.
E. Percentages of wing position defects in OPMD flies at 188C in the presence or absence of puromycin provided from first instar larval to adult stages. OPMD
males were scored (n¼50–190).
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fibril formation
We propose that 6AP might have a positive effect on OPMD by
interfering with the protein folding activity of ribosomal RNA
and that this activity of ribosomal RNA would play a role in
PABPN1-17ala aggregation. A prediction of this model is that
PABPN1-17ala nuclear inclusions would be altered in the
genetic background of ribosomal DNA deletions that led to a
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Figure 7. The ribosomal RNA is involved in
PABPN1-17ala aggregation and in fibril
formation of its N-terminal domain in vitro.
A. Percentages of nuclear inclusions in OPMD
thoracic muscles at day 11, either in the
presence or absence of bb deletions. In the
presence of bb deletions, quantifications are
indicated both regardless of the wing posture
(bb
N/Df; OPMD), and in subgroups showing or
not wing posture defects (bb
N/Df; OPMD no
rescue, and bb
N/Df; OPMD rescue)‘rescue’
indicates OPMD flies which have normal
wing posture,‘no rescue’indicates flies which
still have an affected wing posture.
B. Quantification of nuclear inclusion areas.
Each nuclear inclusion was delimited in a
focal plan and the surface area was calcu-
lated using Image J. Mean values of the
surface areas are shown in arbitrary units
(top). Distribution of nuclear inclusion sur-
face areas are shown as box plots (bottom).
Legend is as in Fig 5B.
C. Confocal images of nuclear inclusions
visualized with anti-PABPN1 staining. DNA
was revealed with DAPI. Examples of nuclei
without an inclusion (no inclusion), and with
a large inclusion (inclusion) in OPMD thoracic
muscles. Example of a small inclusion in an
OPMD thoracic muscle in the presence of bb
deletions.
D. Kinetics of fibril formation of the PABPN1-
17ala N-terminal domain, either in the pre-
sence or absence of ribosomal RNA domain V,
monitored by ANS fluorescence. tRNA was
used as a negative control.
E. Electron micrographs of oligomers or fibrils
of PABPN1-N-17ala formed in vitro, either in
the presence or absence of ribosomal RNA
domain V.
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percentage and size of PABPN1-17ala nuclear inclusions
showed that, similarly to what was observed after oral
treatments with 6AP or GA, the number of nuclear inclusions
was not affected, but their size was signiﬁcantly reduced in
bb
N/Df(1)17-87 deleted ﬂies, compared to the wild-type
ribosomal DNA background (Fig 7A–C).
We next analyzed a potential direct effect of the ribosomal
RNA on PABPN1-17ala aggregation using in vitro assays. We
previously used the N-terminal domain of PABPN1 (PABPN1-N:
residues 1-125 of 306) to monitor ﬁbril formation in vitro.
Because full-length PABPN1 forms amorphous deposits, the
soluble N-terminal domain, which contains the polyalanine
tract, was selected for the biophysical analyses (Scheuermann
et al, 2003). Importantly, this domain has no activity in RNA
binding (Kuhn et al, 2003). PABPN1 N-terminal domain was
shown to form ﬁbrils, which have the characteristics of amyloid
ﬁbers, and a polyalanine expansion in this domain (PABPN1-N-
17ala) strongly accelerates ﬁbril formation (Scheuermann et al,
2003). The protein folding activity of ribosomal RNA is borne by
the domain V of the large ribosomal RNA. We therefore
analyzed the capacity of this RNA domain to inﬂuence ﬁbril
formation of PABPN1-N-17ala in vitro. PABPN1-N-17ala protein
samples were incubated at 1mM, either in the presence or the
absence of 1mMo fDrosophila domain V RNA, and analyzed for
binding to 1-anilino-8-naphtalensulfonate (ANS), as a measure
ofﬁbrilformation.IntheabsenceofdomainVRNA,ANSsignals
roseafter alagphase of 10days (Fig 7D). Strikingly,the addition
of domain V RNA led to an immediate increase in ANS
ﬂuorescence (Fig 7D). This effect was observed neither when
PABPN1-N-17ala was mixed with 1mM transfer RNA (tRNA),
nor when ribosomal RNA domain V was incubated alone
(Fig 7D).
The presence of ﬁbrils was conﬁrmed using EM. After 5 days
of incubation, PABPN1-N-17ala alone only formed oligomers,
which then started to convert into short ﬁbrils after 14 days of
incubation (Fig 7E, left panels). When PABPN1-N-17ala was
incubated in the presence of ribosomal RNA domain V, ﬁbrils
had already formed after 5 days, and they had converted into
long, unbranched ﬁbrils after 14 days (Fig 7E, right panels). We
conclude that the domain V of the large ribosomal RNA
accelerates the formation of PABPN1-N-17ala ﬁbrils in vitro.
It should be noted that the effects of 6AP and GA could not be
analyzedintheseinvitroassaysasbothdrugsprecipitatedinthe
protein incubation buffer, and DMSO alone affected ANS
ﬂuorescence.
Taken together, these in vivo and biophysical data strongly
support an important role of the ribosomal RNA in the
aggregation process of PABPN1-17ala and its assembly as
nuclear inclusions in vivo.
DISCUSSION
Our results using the Drosophila model of OPMD demonstrate
that the antiprion drugs 6AP and GA have a protective and, to
some extent, a curative effect for OPMD. We further show that
these drugs reduce the aggregation load of alanine expanded
PABPN1. When larvae and adults are fed with 6AP and GA,
respectively, PABPN1-17ala nuclear inclusions are smaller.
Together with the reduced muscle degeneration, these results
suggest that both drugs interfere with the aggregation process,
potentially slowing down a conformational change that would
be involved in both aggregate formation and impairment of
PABPN1 function.
We have recently shown that 3F5, an intrabody against
PABPN1, prevents OPMD phenotypes when co-expressed with
PABPN1-17ala in Drosophila muscles. Interestingly, 3F5 has an
effect similar to that of 6AP or GA on PABPN1-17ala nuclear
inclusions. When 3F5 is co-expressed with PABPN1-17ala, the
number of muscle nuclei showing an inclusion is similar to that
observed without the intrabody, but the sizes of the nuclear
inclusions are smaller (Chartier et al, 2009). The relationships
between the formation of nuclear inclusions and the disease
process have not been clariﬁed. In other words, it is not yet
known whether a speciﬁc conformer of PABPN1-17ala is toxic
and participates in the disease symptoms, or whether the
mutation leads to two independent phenomena: protein
misfunction and aggregation, aggregates being a read-out of,
but not directly involved in, the disease process.
We have shown previously that the normal function of
PABPN1 and more speciﬁcally its activity in RNA binding is
required for OPMD pathology (Chartier et al, 2006). Moreover,
we have also reported that muscle defects can be uncoupled
from the presence of aggregates, for example when a deleted
form of PABPN1 without the polyalanine tract is expressed in
muscles (Chartier et al, 2006). Together, these data led us to
propose that the early defects in OPMD would depend on
PABPN1function andthataggregateformationmightcontribute
to pathogenesis during later stages when aggregates reach a
large portion of nuclei, thus altering nuclear function.
Both the 3F5 intrabody and the 6AP and GA compounds have
strong effects in decreasing muscle degeneration and also
reduce the PABPN1-17ala aggregation load. This indicates that
at least one step is common to the aggregation process and the
pathology. It could be a conformational change of PABPN1-
17ala that might affect the function of the protein and would
eventually lead to the formation of aggregates.
Recent data on polyglutamine diseases also reveal an
essential role of normal protein functions in pathogenesis
(Duvick et al, 2010; Nedelsky et al, 2010). These data led to a
modelinwhichthe normalproteinexists inatleasttwo different
conformations that would be responsible for two different
normal functions. Extension of the polyglutamine tract would
favour one conformer, thus disturbing the equilibrium and
leading to both the gain of function of one conformer and the
lack of function of the other (Kratter & Finkbeiner, 2010). One
possibility could be that the conformer that is stabilized upon
mutation could eventually form aggregates. This model is
particularly suited for OPMD as the normal protein has been
shown to assemble in aggregates under speciﬁc physiological
conditions (Berciano et al, 2004).
A major piece of information presented here is the fact that
GA has a strong effect in preventing OPMD pathology in the
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drugs with a good efﬁcacy in mammalian models for speciﬁc
diseases, in particular neurodegenerative disorders (Marsh &
Thompson, 2004). GA is used routinely in the clinic as an
antihypertensive drug (Holmes et al, 1983). It has been
administrated for many years to patients on a daily basis
without major side-effects. Therefore, our results identify GA as
a strong candidate to be evaluated in potential treatments for
OPMD.
Another important aspect of our results is that they support
the function of the large ribosomal RNA in propagation of
protein aggregation in diseases. In addition to its central
function in protein synthesis, an ability of the ribosome to assist
protein folding has been described (Argent et al, 2000;
Chattopadhyay et al, 1996; Pal et al, 1999; Samanta et al,
2008; Sanyal et al, 2002). More speciﬁcally, this activity is borne
by the domain V of the large ribosomal RNA. 6AP and GA have
antiprion properties both in yeast and in mammalian systems
(Bach et al, 2003; Tribouillard et al, 2006; Tribouillard-Tanvier
et al, 2008a). These compounds bind to speciﬁc positions in
domain V of the large ribosomal RNA and prevent its activity in
protein folding, without affecting its function in protein
synthesis (Tribouillard-Tanvier et al, 2008b). Together, this
set of data suggests that the large ribosomal RNA has a function
in prion propagation, and that this function is prevented by
directinteractionswith6APorGA,thusleadingtoreducedprion
stability or propagation. Here, we show the beneﬁt of 6AP and
GA in vivo on a physiological defect, namely muscle degenera-
tion. We further ﬁnd that reduced copy number of ribosomal
DNArepeatshasasimilarbeneﬁcialeffectonOPMDphenotypes
and that 6AP acts synergistically with reduced copy number of
ribosomal DNA repeats to decrease OPMD phenotypes. This
providesgeneticevidencethattheribosomalRNAisaconserved
cellular target of 6AP in Drosophila. More importantly, these
data strongly suggest that the ribosomal RNA plays a role in
PABPN1-17ala aggregation in OPMD, and that the beneﬁcial
effect of 6AP on OPMD results from the inhibition of this speciﬁc
function of the ribosomal RNA. Consistent with this, we ﬁnd
that deletions of ribosomal DNA repeats result in the reduced
size of PABPN1-17ala nuclear aggregates. Moreover, we show
that the domain V of ribosomal RNA is able to accelerate ﬁbril
formation of the N-terminal domain of PABPN1-17ala in vitro.
Thisidentiﬁes,fortheﬁrsttime,adirecteffectofthedomainVof
ribosomal RNA on the conformational transition of a protein
domain implicated in a disease.
Because the ribosomal RNA is highly conserved between
species, it is very likely that its function in protein folding and in
aggregatepropagationindiseasesisalsoconserved.6APandGA
speciﬁcally prevent the protein folding activity of the large
ribosomal RNA and are unique in targeting this general cellular
function (Tribouillard-Tanvier et al, 2008b; Voisset et al, 2008).
This could be the basis for the widespread effect of 6AP and GA.
The antiprion activity of both drugs was evidenced with
different, unrelated prion proteins, both in terms of sequence
and function, and in different organisms ranging from yeast to
mammals (Bach et al, 2003; Tribouillard et al, 2006;
Tribouillard-Tanvier et al, 2008a). In addition, we demonstrate
here the protective effect of 6AP and GA on a different protein
aggregation disease, and in Drosophila, yet another model
system. Because of the speciﬁc function of PABPN1 in RNA
metabolism (Benoit et al, 1999, 2005; Lemay et al, 2010; Wahle,
1991), we cannot exclude an additional role of the ribosomal
RNA in OPMD pathogenesis that could also be modiﬁed by 6AP
and GA. However, our biophysical approach shows a direct role
of domain V of ribosomal RNA on the conformational change of
a PABPN1 domain that is not involved in RNA binding.
This study, in addition to the widespread antiprion effect of
6AP and GA, suggests that 6AP and GA might have a general
role in preventing protein aggregation and that they might be
beneﬁcial for other major protein aggregation neurodegenera-
tive disorders.
MATERIALS AND METHODS
Fly stocks, drug supplemented medium and analysis of drug
toxicity
The Gal4 driver was Mhc-Gal4 (Schuster et al, 1996), which induces
expression in muscles. UAS-PABPN1-17ala has been described
previously (Chartier et al, 2006). The crosses were performed at
188C to allow a slow progression of OPMD phenotypes (Chartier et al,
2006). OPMD males were scored, except in the experiments with the
bobbed (bb) deletions. w
1118 stock was used as the wild-type control.
bb
N is a weak allele of bb (FlyBase: http://flybase.org/) and Df(1)17-87
corresponds to a deficiency including the bb locus (Schalet & Lefevre,
1973). Drug supplemented food was prepared as follows. Instant
Drosophila medium (Carolina Biological Supply Company) was
reconstituted in each vial with a solution of 1% yeast in water,
supplemented with either increasing concentrations of drug diluted in
DMSO (Sigma D2650), or DMSO alone. Puromycin was diluted in
water. Except for 6AP and 6APi, the drugs were purchased (Sigma) as
follows: puromycin dihydrochloride (P8833), doxycycline hydrate
(D9891), D-(þ)-trehalose dihydrate (T9531), ibuprofen sodium salt
(I1892), guanabenz acetate salt (G110). Each vial contained 5 or 2ml
of reconstituted medium, to raise larvae or adults, respectively. When
individuals were fed with the drugs from larval stages, 70–80 first
instar larvae were transferred per vial and developed in the same vial
up to adulthood; adults were transferred in a new vial with the same
concentration of drug.To determine drug toxicity, 80 first instar larvae
were transferred into vials containing drug- or DMSO alone-
supplemented medium. Individuals reaching adulthood were scored.
Analysis of wing position and adult musculature
Abnormal wing position and visualization of thorax muscles under
polarized light were determined as described previously (Chartier et al,
2006).
Immunohistochemistry and western blots
Western blots and immunostaining of adult IFMs were performed as
reported previously (Chartier et al, 2006). Rabbit anti-PABPN1
antibody was used at dilution 1:1000. Thoracic muscles of 10–15
adults were stained per experiment and nuclei were scored for the
presence or absence of nuclear inclusions; scoring was performed from
two independent staining experiments.
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Recombinant gene expression and protein purification of the
N-terminal domain of PABPN1 containing seven additional alanine
residues, PABPN1-N-17ala was performed as published for CspB
fusions (Sackewitz et al, 2008) except that heat precipitation was
performed for 5min at 808C. PABPN1-N-17ala was dissolved to a final
concentration of 1mM and incubated at 378C in 5mM KH2PO4,
100mM NaCl at pH 7.5, containing 1mg/ml NaN3 and 0.8U/ml
RiboLock
TM RNase Inhibitor (Fermentas, Germany), either in the
presence or absence of RNA. Domain V (747 nt) of the Drosophila 28S
ribosomal RNA was produced using in vitro transcription (Fermentas,
Germany) and a PCR fragment amplified with primers
50TAATACGACTCACTATAGGGGATATTAGACCTCGGTTTGGTATCG (T7 promo-
ter sequence is underlined) and 50TGTGCCATTGGTCCGTACCTGCGGG, as a
template. The RNA was phenol-chloroform extracted, precipitated and
resuspended in H2O. The control experiment with an irrelevant RNA
was performed with tRNA (Applied Biosystems, USA). ANS fluorescence
was determined as described previously (Sackewitz et al, 2008). For
EM analysis, carbonized copper grids (Plano, Wetzlar, Germany) were
prepared as published (Lodderstedt et al, 2007) and visualized with a
Zeiss EM 900 EM operating at 80kV.
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